Medicare GLP-1 Coverage: What the 2026 Changes Mean

Medicare and GLP-1 medications have had a complicated relationship. For years, federal law prohibited Medicare from covering weight-loss drugs. That's changing in 2026 — but the details matter, and the new coverage comes with significant caveats.

The History: Why Medicare Hasn't Covered Weight-Loss Drugs

The Medicare Modernization Act of 2003 explicitly excluded coverage for drugs prescribed solely for weight loss or cosmetic purposes. This blanket exclusion meant that even as GLP-1s proved remarkably effective for obesity, Medicare beneficiaries had to pay full price — often $1,000+ per month — or go without.

The only exception: GLP-1s prescribed for an FDA-approved indication other than weight loss. This meant Medicare already covered Ozempic and Mounjaro for type 2 diabetes, and Wegovy for cardiovascular risk reduction in patients with established heart disease.

What's Changing in 2026

The Medicare GLP-1 Bridge Program

Starting July 1, 2026, CMS will provide Part D beneficiaries with coverage of select GLP-1 medications specifically for the weight loss indication:

• Covered medications: Wegovy (injectable and oral semaglutide) and Zepbound (tirzepatide)
• Copay: $50/month for eligible beneficiaries
• Duration: July 1, 2026 through December 31, 2027 (originally Dec 2026, extended)
• Eligibility: Medicare Part D beneficiaries who meet clinical criteria for obesity treatment
• No compounded versions: Only FDA-approved brand-name products are covered

Most-Favored-Nation (MFN) Pricing

The Trump administration struck MFN deals with both Novo Nordisk and Eli Lilly, setting the Medicare/Medicaid price for semaglutide and tirzepatide at $245 per month. This negotiated price enables the $50 copay structure of the Bridge program and will also apply to state Medicaid programs.

The BALANCE Model (2027+)

Beyond the Bridge, CMS has proposed the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model — a 5-year demonstration program:

• Part D plans can voluntarily participate starting January 2027
• Covers GLP-1 weight-loss medications for Medicare and Medicaid beneficiaries
• If fewer than 80% of Part D plan sponsors participate, CMS may not launch the Medicare portion
• Semaglutide is also selected for Medicare drug price negotiation with a negotiated price taking effect in 2027

What Medicare Beneficiaries Should Do Now

What Medicare Does NOT Cover

• Compounded semaglutide or tirzepatide — not covered under any Medicare program
• GLP-1s prescribed purely for cosmetic weight loss (without documented medical necessity)
• Off-label use of diabetes GLP-1s for weight loss (Ozempic for weight loss without a T2D diagnosis)
• Medications from non-participating pharmacies — must go through a Part D network pharmacy

Bottom Line

Medicare GLP-1 coverage is expanding dramatically in 2026. The Bridge program starting July 1 will offer Wegovy and Zepbound for weight loss at a $50/month copay — a massive shift for Medicare beneficiaries who've been paying $1,000+ out of pocket. However, the program is temporary, compounded versions remain uncovered, and long-term access depends on the BALANCE Model's uncertain rollout. If you're a Medicare beneficiary who needs GLP-1 medication now, compounded options are the most affordable path while you wait for Bridge coverage to begin.

Compare Providers

Licensed telehealth platforms verified by our editorial team. All links are clearly marked as paid.

Affiliate Disclosure: We may earn a commission when you sign up through our links. This supports independent research and keeps this resource free. Rankings are based on pharmacy certifications, pricing transparency, and patient outcomes — not commission rates. Compounded medications are not FDA-approved.

You Might Also Like